CommentCall for withdrawal of LABA single-therapy inhaler in asthma
References (12)
- et al.
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies
J Allergy Clin Immunol
(2004) - et al.
Adherence to asthma controller medication regimens
Respir Med
(2005) - et al.
Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy
Thorax
(2010) - et al.
Risk of mortality associated with formoterol: a systematic review and meta-analysis
Eur Respir J
(2009) - et al.
The risk of asthma mortality with inhaled long acting beta-agonists
Postgrad Med J
(2008) Balancing the benefits and risks of inhaled long-acting beta-agonists—the influence of values
N Engl J Med
(2009)
Cited by (36)
Current Management of Asthma
2021, Encyclopedia of Respiratory Medicine, Second EditionGranulocyte-targeted therapies for airway diseases
2020, Pharmacological ResearchCitation Excerpt :Short-acting β2-agonists (SABA) provide short-term relief (onset of action in 5 min, duration 4−6 h), while long-acting β2-agonists (LABA) deliver a longer (more than 12 h) bronchodilation [62]. The reduction of AHR by LABA without abating the airway inflammation, leads to false perception of controlling the disease, and result in uncontrolled progression of the inflammatory process [95]. For controlling airway inflammation and preventing damage/remodeling of the airways, inhaled corticosteroids (ICS) are the first line of treatment and, in combination with LABA, they are regarded as the gold standard in the management of asthma.
Management of mild asthma in 2019–2020: What about new international therapeutic proposals (GINA 2019)?
2020, Revue des Maladies RespiratoiresLong-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids
2017, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Moreover, an important advantage of combining ICS and LABA in 1 inhaler is the prevention of LABA use as monotherapy, which carries potential increased risk of asthma-related mortality. Since 2005, LABA monotherapy has been accompanied by a Food and Drug Administration (FDA) “black box” warning in the United States.35,36 In 2010, the FDA recommended the use of FDC products to ensure compliance with concomitant therapy in pediatric and adolescent patients.37
Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma
2016, Respiratory MedicineCitation Excerpt :Patients were all taking maintenance ICS prior to randomised treatment administration, suggesting that the observed bronchodilator response is likely to have been due mainly to the VI component. VI was administered in the combination FF/VI ELLIPTA DPI, as this is the formulation in which VI will be available for use in adults with asthma; there is no separate VI inhaler product available for use in adults with asthma, thereby avoiding possible LABA monotherapy, if ICS and LABA therapy is prescribed as separate inhalers [32]. Although both the FF/VI 100/25 mcg and 200/25 mcg preparations are the once-daily doses recommended in asthma, based on the clinical trials in which efficacy has been demonstrated [16–18], we examined the FF/VI 100/25 mcg preparation as this is the dose likely to be most commonly used in clinical practice.
Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects
2016, Pulmonary Pharmacology and Therapeutics